Valutazione dell'efficacia del Neotelio FT nel trattamento delle ferite aperte croniche
Valutazione dell'efficacia del Neotelio Ft nella guarigione di ferite aperte croniche: uno studio multicentrico controllato randomizzato
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care (SOC) alone, or SOC plus NeoThelium FT.
The study includes a crossover component for subjects in the SOC arm. At treatment visit 13 (approximately 84 days post-randomization), SOC arm subjects not having achieved complete wound closure, and still meeting the inclusion/exclusion criteria, are eligible to cross over to the IP arm (SOC plus NeoThelium FT). Crossover subjects will begin IP arm treatment with weekly NeoThelium FT applications for up to 12 treatment visits. The subject will continue follow-up per the original schedule. As this is a post-marketing study, it will gather information regarding the efficacy of treatment while also supporting insurance reimbursement decisions. All subjects will complete two-week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 12 weeks. Secondary endpoints consist of wound percentage area reduction rates and pain assessment.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Angelina Ferguson, DNP
- Numero di telefono: (985) 629-4013
- Email: info@sygnola.com
Backup dei contatti dello studio
- Nome: Sarah Moore, MBE
- Numero di telefono: (985) 629-4013
- Email: info@sygnola.com
Luoghi di studio
-
-
Louisiana
-
Denham Springs, Louisiana, Stati Uniti, 70726
- Reclutamento
- MedCentris of Denham Springs
-
Investigatore principale:
- Monique Consoer, NP
-
Contatto:
- Tabatha Yent
- Email: tabatha.yent@medcentris.com
-
Hammond, Louisiana, Stati Uniti, 70403
- Reclutamento
- MedCentris of Hammond
-
Investigatore principale:
- Chris Keaton, NP
-
Contatto:
- Chelsea Smith, RN
- Email: Chelsea.smith@medcentris.com
-
Contatto:
- Melanie Knox, LPN
- Email: Melanie.knox@medcentris.com
-
Lafayette, Louisiana, Stati Uniti, 70507
- Completato
- MedCentris of Carencro
-
Leesville, Louisiana, Stati Uniti, 71146
- Reclutamento
- MedCentris of Leesville
-
Investigatore principale:
- Stefanie Corley, FNP
-
Contatto:
- Brandi Shuff
- Email: Brandi.shuff@medcentris.com
-
Many, Louisiana, Stati Uniti, 71449
- Reclutamento
- MedCentris of Many
-
Investigatore principale:
- Stefanie Corley, FNP
-
Contatto:
- Brandi Shuff
- Email: Brandi.Shuff@medcentris.com
-
Marksville, Louisiana, Stati Uniti, 71351
- Reclutamento
- MedCentris of Marksville
-
Investigatore principale:
- Averie Rachal, FNP
-
Contatto:
- Laura Whittington
- Email: Laura.whittington@medcentris.com
-
Metairie, Louisiana, Stati Uniti, 70001
- Reclutamento
- MedCentris of Metairie
-
Contatto:
- Ninya Powell
- Email: ninya.powell@medcentris.com
-
Investigatore principale:
- Sarah Logrande, NP
-
Minden, Louisiana, Stati Uniti, 71055
- Reclutamento
- MedCentris of Minden
-
Investigatore principale:
- Taheera Forbes, NP
-
Contatto:
- Brianna Thompas
- Email: brianna.thompson@medcentris.com
-
Monroe, Louisiana, Stati Uniti, 71201
- Non ancora reclutamento
- MedCentris of Monroe
-
Investigatore principale:
- Libbi Trawick, NP
-
Contatto:
- Tiffany Dew
- Email: Tiffany.dew@medcentris.com
-
Slidell, Louisiana, Stati Uniti, 70458
- Reclutamento
- MedCentris of Slidell
-
Investigatore principale:
- Katie Schloegel, FNP
-
Contatto:
- Donyille Singletary, RN
- Numero di telefono: 985-602-1215
- Email: Donyille.singletary@medcentris.com
-
-
Mississippi
-
D'Iberville, Mississippi, Stati Uniti, 39540
- Completato
- MedCentris of D'iberville
-
McComb, Mississippi, Stati Uniti, 39648
- Completato
- MedCentris of McComb
-
Natchez, Mississippi, Stati Uniti, 39120
- Completato
- MedCentris of Natchez
-
Southaven, Mississippi, Stati Uniti, 38671
- Reclutamento
- MedCentris of Southaven
-
Investigatore principale:
- Carlene McAllister, NP
-
Contatto:
- De'Nyia Woods
- Email: denyia.woods@medcentris.com
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11234
- Reclutamento
- Northeast Podiatry Consultant
-
Contatto:
- Thomas Hayes
- Email: thomas@simonfootandankle.com
-
Investigatore principale:
- David Simon, DPM, FACFAS
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of >0.7 and <1.3, or TBI of >0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion Criteria:
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of <1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids >10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for >2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: No Intervention: Standard of Care
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading |
|
Sperimentale: Intervention: NeoThelium FT & Standard of Care
Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading |
NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Complete Wound Closure
Lasso di tempo: 1-12 weeks
|
The primary endpoint will be the percentage of target ulcers that achieve complete wound closure. |
1-12 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage Wound Area Change
Lasso di tempo: 1-12 weeks
|
The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination. |
1-12 weeks
|
|
Pain Assessment
Lasso di tempo: Day 0, Day 14, Day 35, Day 56, Day 84
|
Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points |
Day 0, Day 14, Day 35, Day 56, Day 84
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Follow-Up Closure
Lasso di tempo: 2 weeks
|
Number of wounds remaining closed during the 2-week follow-up |
2 weeks
|
|
Adverse Events and Serious Adverse Events
Lasso di tempo: Day -14 through 91 days
|
The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported. |
Day -14 through 91 days
|
|
Time to Closure
Lasso di tempo: 1-12 weeks
|
Average number of grafts and/or weeks used to achieve wound closure |
1-12 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Angelina Ferguson, DNP, SygNola, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- HEAL
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .